Also known as

Cathelicidin · hCAP18 fragment · Human antimicrobial peptide LL-37

Overview

LL-37 is the C-terminal antimicrobial peptide derived from human cathelicidin (hCAP18), studied in innate defense, biofilm, and wound models. Literature covers bactericidal assays, immunomodulation, and epithelial repair endpoints.

It is a host-defense peptide research tool, not a cosmetic active claim. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• Antimicrobial and antibiofilm endpoints

• - Innate immune modulation markers

• - Wound and epithelial repair readouts where studied

• - Chemotaxis and host-defense signaling measures

• - Comparative cathelicidin pharmacology in infection models

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early matrix, skin, or antimicrobial readouts in topical/in vitro models.

• - Week 3–4: Clearer collagen, expression-line, or barrier markers in short research windows.

• - Month 2–3: More apparent cosmetic-endpoint changes in extended laboratory designs.

• - Month 3–6: Sustained skin/matrix observations where longer protocols are studied.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.